Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25859956 | 1.00 | GPR119 (0.37) | GPR119ABCB1KDM4EALDH1A1GLA | |
| SCHEMBL25859957 | 0.91 | GPR119 (0.35) | GPR119ABCB1PIK3R1PIK3CA | |
| SCHEMBL25650391 | 0.90 | GPR119 (0.38) | GPR119ABCB1PIK3R1PIK3CAUSP30 | |
| SCHEMBL25859958 | 0.88 | ABCB1 (0.32) | GPR119ABCB1PIK3R1PIK3CAUSP30 | |
| SCHEMBL25650412 | 0.87 | GPR119 (0.38) | GPR119ABCB1PIK3R1PIK3CAUSP30 | |
| SCHEMBL25650532 | 0.87 | GPR119 (0.36) | GPR119ABCB1PIK3R1PIK3CA | |
| SCHEMBL25650266 | 0.87 | GPR119 (0.36) | GPR119ABCB1PIK3R1PIK3CA | |
| SCHEMBL25650326 | 0.86 | HSD11B1 (0.34) | GPR119ABCB1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL25622588 | 0.85 | ABCB1 (0.32) | GPR119ABCB1KDM4EALDH1A1GLA | |
| SCHEMBL25650492 | 0.83 | GPR119 (0.37) | GPR119ABCB1SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | GPR119 1460/4885ABCB1 127/4885KDM4E 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.